CD8A and glioblastoma: Given that CMV-DCs can trigger a CMV-specific CD8+ T-cell response [103, 104], they further conducted a pilot trial in which newly diagnosed GBM patients received both CMV pp65-specific T cells and a CMV-DC vaccine [106].